Cancer immunotherapy has emerged as a major component of cancer treatment. This symposium aims to catalyze new approaches to anti-cancer immunity in settings where it is currently limited by bringing together bioengineers, cancer immunologists, and oncologists.
Mechanisms of Protective Tumor Immunity
Glenn Dranoff, M.D.
Single-cell sequencing of T cells in food allergy
J. Christopher Love, Ph.D.
Massachusetts Institute of Technology
Moving Forward CAR T Cell Therapies for Multiple Myeloma and Beyond
Eric Smith, M.D., Ph.D.
Dana-Farber Cancer Institute
Immunotherapeutic Drug Delivery to Lymph Nodes Augments Cancer Immunotherapy
Susan Thomas, Ph.D.
Molecular Understanding of T Cell Exhaustion and Role in Disease
E. John Wherry, Ph.D.
Perelman School of Medicine, University of Pennsylvania
The Harvard i3 Center is part of NIH’s Cancer Moonshot initiative that was formed to accelerate cancer research to make more therapies available to more patients, while also improving the ability to prevent cancer and detect it at an early stage.